is this why fda delays are getting longer?, page-24

Gwaihir

This industry is very incestuous - companies can be in bed with each other on one product, whilst at the same time competing in the same market with another product.

In saying this, there are definitely dirty deals done in back rooms.

However, in 2011, for the FDA to collude, I'm not so sure - there is way too much at risk.

In terms of which pharma to select, not so easy. Go with a well known US/European Big Pharma and they can play you like a puppet - Biota has wasted an opportunity and lost big opportunities with its first generation antiviral, by giving it to GSK, who have all sorts of other agendas.
Alternatively, go with a not so high profile pharma and you can do a better deal, have more say, but then there are other disadvantages.

Approval will come and then all will be praising ACL management for their decisions.